Developing a Non-Invasive Screening Test for Nasopharyngeal Carcinoma


Epitech is a private Healthcare Services company. We hold the worldwide, exclusive license to provide a screening test developed by Oxford Biodynamics Plc (OBD), a UK publicly listed biotech company spun out from the University of Oxford. OBD has a laboratory in Penang, as well as a headquarters in Oxford, UK. The screening test in question is a blood test that requires 5ml of peripheral blood. It tests for nasopharyngeal carcinoma, or NPC, the 4th most common cancer in Malaysian men, particularly prevalent in those of Chinese descent. The test works by picking out epigenetic biomarkers that signal the presence of NPC. Epigenetics is a cutting edge scientific advance, with the potential to revolutionize diagnostics. With the test in the final stage of development, and positive results expected, Epitech is looking to raise funds for business development capital in Malaysia and Singapore. The objective is to penetrate the major private healthcare centres, selling the test through laboratory distributors.

Epitech doesn't have any updates to show yet.

Please login or sign up to see the discussions.



Equity Crowdfunding is risky. You are investing in early stage companies which may not do well and could even fail. You could lose part or all of your investment. You may not be able to sell your shares easily.

Investments are speculative and carry high risks. To decrease exposure, these types of investments should only be made as part of a diversified portfolio. Spread your risks and only invest money that you can afford to lose. pitchIN wants all investors to understand these risks and make careful investment decisions. You are also encouraged to seek independent advice.